reports
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infe...
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035. “We thank the China National Intellectual Property Administration for their recognition of the significant potenti...
- Sean Conroy
Recce Pharmaceuticals - Advances on several fronts
Recce Pharmaceuticals has reported several encouraging developments in recent weeks for its lead development compound RECCE® 327 (R327). The intravenous (IV) R327 formulation is advancing to a higher dose level (4,000mg) in its ongoing Phase I/II rapid infusion study and the company is progressing in its plan to submit a US Investigational New Drug (IND) application to commence a US Phase II complicated urinary tract infection (cUTI) study before end-CY24. Recce is also planning to start an Indo...
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of...
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects, with dosing to start in near weeksR327 dosed at 3,000mg has successfully been tested at various infusion times (15, 20, 30, 45 minutes, and 1 hour)Minimum Inhibitory Concentration (MIC) activity identified among existing clinical samples, a dose optimization exercise for regulatory purposes SYDNEY, Aus...
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Go...
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP) Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaignR327 manufactured under GMP standards in support of current and anticipated clinical trials, demonstrating compliance with guidelines set by regulatory authorities, such as the U.S. Food and Drug Administration (FDA) SYDNEY, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synt...
Recce Pharmaceuticals Provides Business Update
Recce Pharmaceuticals Provides Business Update Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens during testing with Linnaeus BioscienceU.S. Departmen...
Recce Pharmaceuticals Selected by UK Government Innovation Agency to P...
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024 Recce recognized by the United Kingdom Government Innovation Agency among the most promising organizations for the UK AMR Inward Mission 2024Recce chosen as one of 18 organizations globally for its potential to tackle the global health threat of AMR and superbugsProfessor Dame Sally Davies, former England Chief Medical Officer, hosting a reception with selected organizations offering Recce strategic partnering opportunities in the AMR space SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIR...
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Inf...
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041. “We are thrilled to have received this newly granted patent in Isra...
- Sean Conroy
Recce Pharmaceuticals - R&D advance (A$11.18m) extends runway
Recce Pharmaceuticals recently received A$11.18m as an R&D advance credit through an arrangement with Endpoints Capital for the R&D tax credit rebates that Recce expects to receive for FY23/FY24 and FY25. We believe this non-dilutive source of funding should extend Recce’s operating runway into FY25. Recce is also continuing to advance its intravenous (IV) R327 formulation in its ongoing Phase I/II study in healthy volunteers, having recently started the 20-minute (3,000mg) dosing cohort. We hav...
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada,...
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been issued a trademark registration for RECCE® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio. The International Trademark Registration No. 1289603 formally assigns RECCE® the Canada Trademark No. 1225479 under Class 5 for antibiotic...
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of R...
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis Four healthy subjects dosed with RECCE® 327 at 3,000mg over 20 minutesData received from this cohort will support preparations for a Phase II trial SYDNEY, Australia, March 19, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed dosing healthy subjects in the latest cohort of its Phase I/II trial, evaluating its lead candidate, RECCE® 327 ...
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® ...
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming daysRECCE® 327 now tested at four infusion times, achieving these timestamps in line with intended future regulatory submissions SYDNEY, Australia, March 14, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it dosed the next cohort...
Recce Pharmaceuticals to Present at the American Society for Clinical ...
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a poster presentation of data from a Phase 1 study evaluating the safety of its lead asset, RECCE® 327, at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado. Details for...
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Develop...
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance SYDNEY, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it received AUD $11,178,965 as a research and development (R&D) advance with Endpoints Capital, capturing Recce’s R&D tax incentive for the 2023/2024 fiscal year (FY23/24) and 2025 fiscal year (FY25). Recce received $11.17 million in non-dilutive cash, reflecting R&D rebate credits for FY23/24, in addition...
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Chi...
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute SYDNEY, Australia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced the continuation of work within its Anti-Infective Research (AIR) Unit at the Murdoch Children’s Research Institute (MCRI), to streamline its ongoing preclinical programs while investigating new indications for future clinical trials. In 2023, Recce established its dedicated AIR Unit led by research...
Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE...
Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections Independent Safety Committee unanimously agrees that the Phase I/II trial is safe, well tolerated, and fit for expanded accessStudy achieving primary endpoints of safety, tolerability, and efficacy by resolving/curing bacterial infections in patients with diabetic foot ulcersRECCE® 327 dosed daily or every second day for 14 days is considered to be safe and well-toleratedAdditional clinical sites to be launched in Australia, and additional clinical trials will be launche...
- Sean Conroy
Recce Pharmaceuticals - Supportive advancements on the pipeline
Recce Pharmaceuticals has announced several positive developments in recent weeks relating to its therapeutic programmes, particularly for lead anti-infective candidate RECCE® 327 (R327). It entered a strategic collaboration with an Indonesian biomedical company, PT Etana Biotechnologies (Etana), which may support the engagement of relatively lower-cost clinical trial sites with potentially deep patient pools in South-East Asia (SEA). The company also recently disclosed positive efficacy results...
Recce Pharmaceuticals Establishes Strategic Partnership in South-East ...
Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana BiotechnologiesMoU aims to facilitate late-stage clinical trials in Indonesia, supporting the Indonesian Government’s access to novel infectious disease medicinesOpportunity to access 10 ASEAN member states1 covering a population of 670 million inhabitantsPatient populations readily available focused on significant unmet medical needs particular to the regionSignificant bilateral initiative supported b...
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of REC...
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections Phase I/II trial assessing the safety and efficacy of RECCE® 327 (R327), a broad-spectrum anti-infective as a topical treatment, met all primary endpointsR327 was well-tolerated in all patients, resolving mild skin and soft tissue diabetic foot infections (DFI), including multidrug-resistant Gram-positive and Gram-negative pathogensData supports imminent domestic and international site expansion SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuti...
- Sean Conroy
Recce Pharmaceuticals - Landmark commitment helps fund R&D costs
Recce recently reported that the Australian government has committed to providing up to A$55m in future cash rebates to reimburse upcoming R&D expenditure directed towards the company’s proprietary synthetic anti-infective programmes to June 2025. Notably, this binding agreement with the Australian government’s Department of Industry, Science and Resources (AusIndustry) extends the rebate programme that customarily reimburses 43.5% of eligible R&D expenditures incurred within Australia, to cover...
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding fo...
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it was awarded an Advanced Overseas Finding for $43,774,907 of a synthetic antibiotic Research & Development (R&D) applicable expenditure by AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science. “We would like to express our gratitud...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.